MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Regeneron Pharmaceuticals Inc

Open

SectorGezondheidszorg

596.73 0.49

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

583.66

Max

599.49

Belangrijke statistieken

By Trading Economics

Inkomsten

-423M

918M

Verkoop

69M

3.8B

K/W

Sectorgemiddelde

14.641

57.333

EPS

12.07

Dividendrendement

0.63

Winstmarge

24.219

Werknemers

15,106

EBITDA

-534M

1.1B

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+47.02% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.63%

2.63%

Volgende Winsten

29 apr 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-13B

62B

Vorige openingsprijs

596.24

Vorige sluitingsprijs

596.73

Technische score

By Trading Central

Vertrouwen

Very Strong Bullish Evidence

Regeneron Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 feb 2025, 12:13 UTC

Winsten

Regeneron 4Q Revenue Up on Strong Sales of EYLEA HD

22 apr 2025, 10:51 UTC

Top Nieuws

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ

28 feb 2025, 12:00 UTC

Top Nieuws

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4 feb 2025, 11:58 UTC

Winsten

Regeneron 4Q Rev Up on Strong Sales of EYLEA HD

4 feb 2025, 11:37 UTC

Winsten

Regeneron Pharma Sees 2025 Adjusted R&D $5B-$5.2B >REGN

4 feb 2025, 11:37 UTC

Winsten

Regeneron Pharma Sees 2025 Gross Margin on Net Product Sales 87%-88% >REGN

4 feb 2025, 11:36 UTC

Winsten

Regeneron Pharma Sees 2025 Capital Spending $850M-$975M >REGN

4 feb 2025, 11:35 UTC

Winsten

Regeneron Pharma Declares Initial Quarterly Dividend of 88c >REGN

4 feb 2025, 11:35 UTC

Winsten

Regeneron Pharma 4Q Adj EPS $12.07 >REGN

4 feb 2025, 11:34 UTC

Winsten

Regeneron Pharma 4Q U.S. Net Sales for Eylea HD, Eylea Rose 2% to $1.5B >REGN

4 feb 2025, 11:34 UTC

Winsten

Regeneron Pharma: 4Q Dupixent Global Net Sales Recorded by Sanofi Rose 15% to $3.7B >REGN

4 feb 2025, 11:32 UTC

Winsten

Regeneron Pharma Board OKs Additional $3 Billion Share Repurchase >REGN

4 feb 2025, 11:31 UTC

Winsten

Regeneron Pharma Initiates Quarterly Cash Dividend Program >REGN

31 jan 2025, 08:30 UTC

Acquisities, Fusies, Overnames

It's Bananas, but Stock Splits Can Pay Off. Here Are 5 Likely Contenders. -- Barrons.com

28 jan 2025, 10:30 UTC

Top Nieuws

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

31 okt 2024, 13:58 UTC

Winsten

Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom -- IBD

31 okt 2024, 10:52 UTC

Winsten

Regeneron Earnings Top Views For Biotech Giant -- IBD

31 okt 2024, 10:34 UTC

Winsten

Regeneron Pharma 3Q Adj EPS $12.46 >REGN

31 okt 2024, 10:33 UTC

Winsten

Regeneron Pharma 3Q EPS Cut 43c by Acquired IPR&D Charge >REGN

31 okt 2024, 10:33 UTC

Winsten

Regeneron Pharma 3Q U.S. Sales for Eylea HD, Eylea Rose 3% to $1.54B >REGN

31 okt 2024, 10:32 UTC

Winsten

Regeneron Pharma: 3Q Dupixent Global Net Sales Recorded by Sanofi Rose 23% to $3.82B >REGN

31 okt 2024, 10:30 UTC

Winsten

Regeneron Pharma 3Q Rev $3.72B >REGN

31 okt 2024, 10:30 UTC

Winsten

Regeneron Pharma 3Q EPS $11.54 >REGN

31 okt 2024, 10:30 UTC

Winsten

Regeneron Pharma 3Q Net $1.34B >REGN

25 okt 2024, 20:25 UTC

Winsten

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

1 aug 2024, 11:50 UTC

Winsten

Regeneron Stock Climbs After Strong Second-Quarter Performance -- IBD

1 aug 2024, 10:37 UTC

Winsten

Regeneron Pharma 2Q Adj EPS $11.56 >REGN

1 aug 2024, 10:30 UTC

Winsten

Regeneron Pharma 2Q EPS $12.41 >REGN

1 aug 2024, 10:30 UTC

Winsten

Regeneron Pharma 2Q Net $1.43B >REGN

1 aug 2024, 10:30 UTC

Winsten

Regeneron Pharma 2Q Rev $3.55B >REGN

Peer Vergelijking

Prijswijziging

Regeneron Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

47.02% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 881.75 USD  47.02%

Hoogste 1,120 USD

Laagste 547 USD

Gebaseerd op 21 Wall Street-analisten die 12-maands prijsdoelen bieden voor Regeneron Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

21 ratings

17

Buy

3

Hold

1

Sell

Technische score

By Trading Central

554.18 / 603.77Steun & Weerstand

Korte Termijn

Very Strong Bullish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.